The USC Roski Eye Institute is at the forefront of three separate clinical trials exploring new medications to treat thyroid eye disease (TED), a condition that causes the eyes to bulge and leads to vision loss, double vision and other complications.

Prior to a few years ago, no medication for TED was available. However, the emergence of new drugs has opened the possibility of treating the underlying biology of TED without surgery. Researchers hope that expanding the range of medications on the market will increase the possibility of personalized treatment options, which TED patients often benefit from.

The first and third trials are still enrolling participants. For information on each one, including recruitment details, click here and here.

To read the full story, click here.